Slide 1: Stevanato Group Third Quarter 2022 Financial Results
Stevanato Group Third Quarter 2022 Financial Results November 8th, 2022 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may include forward-looking statements. The words "expect,” “growth”, “rise,” “drive,” “create,” “are managing,” “well positioned,” “continues,” “remain,” “estimate,” and similar expressions (or their negative) identify certain of these forward-looking st
Slide 3: Third Quarter 2022 Earnings Call
overall_1_132557094257415339 columns_1_132557094257415339 71_1_132561414205897258 77_1_132564036149051284 Stevanato Group Third Quarter 2022 Earnings Call Franco Stevanato Executive Board Chairman Franco Moro CEO Marco Dal Lago CFO Lisa Miles SVP IR Q3 2022 FInancial Results
Slide 4: Franco Stevanato, Executive Chairman
Franco Stevanato Executive Chairman Q3 2022 FInancial Results
Slide 5: Strong Fundamentals with Secular Tailwinds in Growing End Markets
overall_1_132557094257415339 columns_1_132557094257415339 71_1_132561414205897258 77_1_132564036149051284 Strong Fundamentals with Secular Tailwinds in Growing End Markets We believe the fundamentals of our business remain strong with favorable secular tailwinds in growing end markets. Successfully
Slide 6: Franco Moro, Chief Executive Officer
Franco Moro Chief Executive Officer Q3 2022 FInancial Results
Slide 7: Q3 2022: Another Solid Quarter of Double-Digit Revenue Growth
Q3 2022: Another Solid Quarter of Double-Digit Revenue Growth Q3 2022 Key Performance Indicators €245.3M Revenue 14% YoY Revenue Growth €65.8M Adj. EBITDA* 26.8% Adj. EBITDA Margin* €0.14 Diluted EPS ~€247M New Order Intake ~€1.0B Backlog ~30% Revenue from HVS €0.14 Adjusted Diluted EPS* *Adjusted D
Slide 8: EZ-fill Smart - The Next Evolution of our Ready-to-Use Platform
EZ-fill Smart™ - The Next Evolution of our Ready-to-Use Platform SG EZ-fill® is a well-established standard in the industrial process for RTU drug containment solutions. This standardization ensures a seamless integration with standard fill & finish operations and offers customers a secure and multi
Slide 9: Progress Update on Strategic Investments in Growth Platforms
Capacity expansion plans are in response to growing demand for high-performance products that help ensure the integrity of highly sensitive treatments such as GLP-1s, monoclonal antibodies, and mRNA applications Already received a warm reception from customers who are pleased with our strategic inve
Slide 10: Stevanato and Bexson Biomedical Recognized for Innovative Pain Management Therapy
Working with Bexson Biomedical to optimize the subcutaneous delivery of a non-opioid pain management treatment that is specifically designed to help prevent misuse through controlled dosing and extended delivery It enables patients to manage their condition at home which lowers cost and improves pat
Slide 11: Marco Dal Lago, Chief Financial Officer
Marco Dal Lago Chief Financial Officer Q3 2022 FInancial Results
Slide 12: Q3 2022: Financial Highlights
Q3 2022: Financial Highlights €245.3 Third Quarter 2022 Revenue 14% Year-over-Year Growth 11% On a Constant Currency Basis in € Millions Q3 2022 Revenue Y/Y revenue increase driven by growth in Biopharmaceutical & Diagnostics segment (BDS) and favorable FX. Covid represented ~13% of revenue in Q3 20
Slide 13: Q3 2022 Segment Financial Summary
Q3 2022 Segment Financial Summary Engineering Segment Revenue Financial results came in as expected. Q3 2022 revenue declined 9% compared to Q3 2021, mostly due to the timing and progression of projects in certain business lines Gross Profit Margin / Operating Profit Margin: Q3 2022 gross profit mar
Slide 14: Strong Balance Sheet with Financial Flexibility
Strong Balance Sheet with Financial Flexibility *Net Cash, CapEx and Free Cash Flow are non-GAAP financial measures. Please refer to pages 18-25 for a reconciliation of non-GAAP financial measures At September 30, 2022 €49.6M Net Cash* €71.1M CapEx* €3.8M Net cash used in Operations €(46.3M) Free Ca
Slide 15: Raising FY2022 Guidance
Raising FY2022 Guidance *Adjusted DEPS and Adjusted EBITDA are non-GAAP financial measures. Please refer to pages 18-25 for a Reconciliation of Non-GAAP financial measures Updated Guidance Prior Guidance Revenue €961M - €971M €955M - €965M Adjusted DEPS €0.52 - €0.54 €0.51 - €0.53 Adjusted EBITDA €2
Slide 16: Franco Moro, Chief Executive Officer
Franco Moro Chief Executive Officer Q3 2022 FInancial Results
Slide 17: Excited for Future Growth Prospects and Opportunities That Lie Ahead
Excited for Future Growth Prospects and Opportunities That Lie Ahead HVS Growth R&D Innovation Multi-Year Pipeline Global Expansion Rise in biologics and biosimilars dovetail with the macro trends of: aging populations, increasing incidence of chronic disease, and shift towards the self-administrati
Slide 18: Financial Measures (Unaudited) Notes to Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures (Unaudited) Notes to Non-GAAP Financial Measures: This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating
Slide 19: Reconciliation of Revenue to Constant Currency Revenue
Reconciliation of Non-GAAP Financial Measures Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions) (Unaudited) Q3 2022 FInancial Results
Slide 20: Reconciliation of EBITDA
Reconciliation of Non-GAAP Financial Measures Reconciliation of EBITDA (Unaudited) (Amounts in € millions) (Unaudited) Q3 2022 FInancial Results
Slide 21: Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Net Profit and Diluted EPS
Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit and Diluted EPS (Unaudited) (Amounts in € millions, except per share data) Reconciliation of Non-GAAP Financial Measures (1) During the three months and nine months ended September 30, 2022, the Group recorded
Slide 22: Free Cash Flow
Reconciliation of Non-GAAP Financial Measures Free Cash Flow (Amounts in € millions) (Unaudited) Q3 2022 FInancial Results
Slide 23: Net Cash
Reconciliation of Non-GAAP Financial Measures Net Cash (Amounts in € millions) (Unaudited) Q3 2022 FInancial Results
Slide 24: Capital Expenditures
Reconciliation of Non-GAAP Financial Measures Capital Expenditures (Amounts in € millions) (Unaudited) Q3 2022 FInancial Results
Slide 25: Reconciliation of 2022 Guidance for Adjusted EBITDA, Operating Profit, Net Profit and EPS
Reconciliation of Non-GAAP Financial Measures Reconciliation of 2022 Guidance for Adjusted EBITDA, Adjusted Operating Profit, Adjusted Net Profit and Adjusted Diluted EPS (Unaudited) (Amounts in € millions, except per share data) Q3 2022 FInancial Results